High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00126854
First received: August 3, 2005
Last updated: March 19, 2012
Last verified: March 2012

August 3, 2005
March 19, 2012
October 2005
April 2011   (final data collection date for primary outcome measure)
pilot study meant to establish scanning parameters on 3T MRSI
-pilot study meant to establish scanning parameters on 3T MRSI
Complete list of historical versions of study NCT00126854 on ClinicalTrials.gov Archive Site
safety/toxicity
-safety/toxicity
Not Provided
Not Provided
 
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation

The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for prostate cancer. Three Tesla MRSI may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.

Not Provided
Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Prostatic Neoplasm
Procedure: Magnetic Resonance Spectroscopy Imaging
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suitable candidate for prostate brachytherapy to treat prostate cancer
  • Patient signs a study consent form

Exclusion Criteria:

  • Have received other radiotherapy for prostate cancer or hormone treatments
  • Has contraindication to MRSI scanning
  • Does not sign study consent form
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00126854
NA-15-0003 / 22011
No
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Not Provided
Principal Investigator: Don Yee, MD AHS Cancer Control Alberta
AHS Cancer Control Alberta
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP